SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022
Share
SCI Pharmtech, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 304.59 million compared to TWD 228.25 million a year ago. Revenue was TWD 304.59 million compared to TWD 228.25 million a year ago. Net income was TWD 48.62 million compared to TWD 29.92 million a year ago. Basic earnings per share from continuing operations was TWD 0.4533 compared to TWD 0.2756 a year ago. Diluted earnings per share from continuing operations was TWD 0.4533 compared to TWD 0.2756 a year ago.
For the nine months, sales was TWD 673.97 million compared to TWD 728.45 million a year ago. Revenue was TWD 673.97 million compared to TWD 728.45 million a year ago. Net income was TWD 230.13 million compared to TWD 75.34 million a year ago. Basic earnings per share from continuing operations was TWD 2.1422 compared to TWD 0.7022 a year ago. Diluted earnings per share from continuing operations was TWD 2.1422 compared to TWD 0.7022 a year ago.
SCI Pharmtech, Inc. is a Taiwan-based company principally engaged in the processing, manufacture and sales of Active Pharmaceutical Ingredients (APIs). The Company's main products include APIs, API intermediates and special and precision chemicals. The Company distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
SCI PHARMTECH, INC. 
